Related Experiment Video

Updated: May 11, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

[Which anticoagulation therapy in old atrial fibrillation patients?]

Jérôme Taieb1

  • 1Centre hospitalier d'Aix-en-Provence, service de cardiologie, 13600 Aix-en-Provence, France. jtaieb@ch-aix.fr

Presse Medicale (Paris, France : 1983)
|May 28, 2013
PubMed

Insights

The European Society of Cardiology (ESC) advises anticoagulation for atrial fibrillation (AF) patients over 75 to prevent ischemic events. Careful evaluation of bleeding risk, particularly with renal issues or low weight, is crucial for these treatments.

Area of Science:

  • Cardiology
  • Pharmacology
  • Geriatrics

Context:

  • Atrial fibrillation (AF) management in elderly patients presents a balance between preventing ischemic events and managing bleeding risks.
  • Current European Society of Cardiology (ESC) guidelines recommend anticoagulation for AF patients aged 75 and older.
  • Newer oral anticoagulation therapies offer benefits but require careful risk assessment.

Purpose:

  • To summarize the ESC recommendations for anticoagulation in elderly AF patients.
  • To highlight the importance of evaluating hemorrhagic risk factors in this population.
  • To discuss the specific considerations for new oral anticoagulation therapy in patients with renal disturbances and low weight.

Summary:

  • ESC recommends Vitamin K antagonists or new oral anticoagulation for AF patients over 75 to reduce ischemic events.
  • Hemorrhagic risk is a significant concern and must be carefully evaluated.
  • Increased bleeding risk is noted in patients with renal impairment and low body weight, particularly with new oral anticoagulants.

Impact:

  • Provides clinicians with essential information for optimizing anticoagulation strategies in elderly AF patients.
  • Emphasizes the need for individualized risk assessment to maximize therapeutic benefits while minimizing adverse events.
  • Contributes to safer and more effective management of atrial fibrillation in geriatric populations.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...